

Title (en)  
ANTAGONISTIC BIPARATOPIC ANTIBODIES THAT SPECIFICALLY BIND FIBROBLAST GROWTH FACTOR RECEPTOR 2 AND METHODS OF USING SAME

Title (de)  
ANTAGONISTISCHE BIPARATOPISCHE ANTIKÖRPER, DIE SPEZIFISCH DEN FIBROBLASTENWACHSTUMSFAKTORREZEPTOR 2 BINDEN, UND VERFAHREN ZU IHRER VERWENDUNG

Title (fr)  
ANTICORPS BIPARATOPIQUES ANTAGONISTES QUI LIENT SPÉCIFIQUEMENT LE RÉCEPTEUR 2 DU FACTEUR DE CROISSANCE DES FIBROBLASTES ET LEURS PROCÉDÉS D'UTILISATION

Publication  
**EP 4161566 A4 20240612 (EN)**

Application  
**EP 21817362 A 20210602**

Priority  
• US 202063033975 P 20200603  
• US 2021035468 W 20210602

Abstract (en)  
[origin: WO2021247718A1] Described and featured herein are antagonistic biparatopic antibodies that specifically bind and inhibit an FGF receptor (e.g., FGFR2) and methods of using such antibodies for the treatment of cancers, including Cholangiocarcinoma (CCAs).

IPC 8 full level  
**C07K 16/28** (2006.01); **A61K 39/00** (2006.01); **A61K 39/39** (2006.01); **A61P 35/00** (2006.01); **C07K 16/30** (2006.01); **C07K 16/32** (2006.01)

CPC (source: EP US)  
**A61P 1/16** (2018.01 - US); **A61P 35/00** (2018.01 - EP US); **C07K 16/2863** (2013.01 - EP US); **C07K 16/30** (2013.01 - EP); **C07K 16/32** (2013.01 - EP); **A61K 2039/505** (2013.01 - US); **C07K 2317/24** (2013.01 - US); **C07K 2317/31** (2013.01 - US); **C07K 2317/35** (2013.01 - EP); **C07K 2317/565** (2013.01 - US); **C07K 2317/73** (2013.01 - EP); **C07K 2317/76** (2013.01 - EP US); **C07K 2317/92** (2013.01 - EP US)

Citation (search report)  
• [Y] WO 2010054265 A2 20100514 - GALAXY BIOTECH LLC [US], et al  
• [A] US 2014322220 A1 20141030 - HARRENGA AXEL [DE], et al  
• [Y] WO 2018014864 A1 20180125 - BEIJING MABWORKS BIOTECH CO LTD [CN]  
• [A] OOSTINDIE SIMONE C. ET AL: "DuoHexaBody-CD37 , a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies", BLOOD CANCER JOURNAL, vol. 10, no. 3, 28 April 2020 (2020-04-28), XP093096471, Retrieved from the Internet <URL:https://www.nature.com/articles/s41408-020-0292-7> DOI: 10.1038/s41408-020-0292-7  
• [A] SALLY YU SHI ET AL: "A biparatopic agonistic antibody that mimics fibroblast growth factor 21 ligand activity", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 293, no. 16, 26 February 2018 (2018-02-26), US, pages 5909 - 5919, XP055722903, ISSN: 0021-9258, DOI: 10.1074/jbc.RA118.001752  
• [A] BARTSCH RUPERT ET AL: "ASCO 2018: highlights in HER2-positive metastatic breast cancer", MEMO - MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, SPRINGER VIENNA, VIENNA, vol. 11, no. 4, 11 October 2018 (2018-10-11), pages 280 - 283, XP036651550, ISSN: 1865-5041, [retrieved on 20181011], DOI: 10.1007/S12254-018-0441-X  
• See also references of WO 2021247718A1

Designated contracting state (EPC)  
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)  
**WO 2021247718 A1 20211209**; AU 2021284297 A1 20230202; CA 3185812 A1 20211209; CN 116367855 A 20230630; EP 4161566 A1 20230412; EP 4161566 A4 20240612; JP 2023528454 A 20230704; US 2023295308 A1 20230921

DOCDB simple family (application)  
**US 2021035468 W 20210602**; AU 2021284297 A 20210602; CA 3185812 A 20210602; CN 202180056915 A 20210602; EP 21817362 A 20210602; JP 2022574398 A 20210602; US 202118008108 A 20210602